Characterisation of putative steroid response elements in the long terminal repeat of HIV-1.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Characterisation of putative steroid response elements in the long terminal repeat of HIV-1.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:102 (poster no. 55). Unique Identifier : AIDSLINE ASHM5/94348914
Barnes N; Deacon N; Doherty R; Macfarlane Burnet Centre, Fairfield, Vic.

Abstract: Motifs with sequence homology to steroid hormone response elements have been identified in the upstream half of the LTR of HIV by several investigators, and nuclear factors have been identified in HeLa cell extracts which bind to these regions. The motifs appear conserved in HIV consensus sequences, and to a variable degree in strains of SIV, CAEV, EIAV and HTLV-I. We have studied the functional capacity of the HIV motifs by transfecting MCF-7 cells with the HIV LTR reporter gene construct pBENNCAT (Cells were cotransfected with pSVTat72). The estrogen responsive construct pVITtkCAT was used as control. The effect of estrogen on HIV LTR controlled transcription was assessed by the CAT activity present in cell lysates. Modest increases in CAT activity were observed in estrogen treated cells. In addition, a nuclear protein present in extracts of estrogen treated MCF-7 and HeLa ER cells was shown to bind to a synthetic oligonucleotide probe containing the ERE-like HIV sequence. Further characterisation of this protein is underway. Mutations have been introduced into the ERE-like region to abolish the element and to substitute the respective RE consensus sequence for the wild type HIV sequence in the reporter gene constructs.

Keywords: Estrogens/*PHARMACOLOGY Hela Cells Human HIV-1/*DRUG EFFECTS/GENETICS Receptors, Estrogen/*DRUG EFFECTS/GENETICS Repetitive Sequences, Nucleic Acid/*DRUG EFFECTS/GENETICS Sequence Homology Transcription, Genetic/DRUG EFFECTS ABSTRACT
941230
M94C4313

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .